On Oct 18, Acelrx Pharmaceuticals Received Written Notice From Nasdaq Notifying Co That It Is Not In Compliance With Minimum Bid Price Requirement; Will Evaluate Available Options To Regain Compliance With Minimum Bid Price Requirement
Portfolio Pulse from Benzinga Newsdesk
AcelRx Pharmaceuticals has received a notice from Nasdaq stating that it is not in compliance with the minimum bid price requirement. The company is evaluating options to regain compliance.
October 20, 2023 | 8:35 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
AcelRx Pharmaceuticals has received a notice from Nasdaq for not meeting the minimum bid price requirement. The company is considering options to regain compliance.
AcelRx Pharmaceuticals' non-compliance with Nasdaq's minimum bid price requirement could lead to its delisting if not rectified. This could negatively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100